4.5 (120) In stock
Despite a few cases of long-responder patients, immunotherapy with anti-PD-(L)1 has so far proved rather disappointing in monotherapy in metastatic breast cancer, prompting the use of synergistic therapeutic combinations incorporating immunotherapy by immune-checkpoint inhibitors. In addition, a better understanding of both the mechanisms of sensitivity and resistance to immunotherapy, as well as the immunological effects of the usual treatments for breast cancer, make it possible to rationally consider this type of therapeutic combination. For several years, certain treatments, commonly used to treat patients with breast cancer, have shown that in addition to their direct cytotoxic effects, they may have an impact on the tumor immune microenvironment, by increasing the antigenicity and/or immunogenicity of a “cold” tumor, targeting the immunosuppressive microenvironment or counteracting the immune-exclusion profile. This review focuses on preclinical immunologic synergic mechanisms of various standard therapeutic approaches with anti-PD-(L)1, and discusses the potential clinical use of anti-PD-1/L1 combinations in metastatic or early breast cancer.
Cancer Drug Resistance indexed in PubMed Central
Cancers, Free Full-Text, papa's burgeria apk
The Healed: Cancer Free - Grand View Church
Cancers, Free Full-Text
Cancers, Free Full-Text, mdpope 3
Cancers, Free Full-Text, jack smith ferreiro
Cancers, Free Full-Text, scp 666 1/2 j
Cancer-Free, Third Edition: Your Guide to Gentle, Non-Toxic
Buy Ring The Bell, I Am Cancer Free Book Online at Low Prices in
Cancer Flyer Template in Publisher - FREE Download
Cancers, Free Full-Text, mdpope 3
Cancers, Free Full-Text, clube aurora ao vivo
Cancers, Free Full-Text, papa's burgeria apk
Cancer Survivor 'Those Magic words 'All Clear' Woo hoo, Cancer
